SCHEMBL600754

SCHEMBL600754

CCNC(=O)Nc1cc(OC(C)C)cc(B2OC(C)(C)C(C)(C)O2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.39
MAPK8 P45983 1/20 0.39
MAPK9 P45984 1/20 0.39
MAPK10 P53779 1/20 0.39
NAMPT P43490 3/20 0.36
HIF1A Q16665 3/20 0.35
MTNR1B P49286 1/20 0.35
PLAU P00749 2/20 0.35
F2 P00734 1/20 0.34
PLG P00747 1/20 0.34
PLAT P00750 1/20 0.34
KLKB1 P03952 1/20 0.34
PRSS1 P07477 1/20 0.34
CA2 P00918 2/20 0.34
PDGFRB P09619 2/20 0.34
KDR P35968 2/20 0.34
ABL1 P00519 1/20 0.34
NR1I2 O75469 1/20 0.34
AAK1 Q2M2I8 1/20 0.33
CA1 P00915 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL600503 0.87 FGFR4 (0.43) NAMPTHIF1APLAUF2PLG
SCHEMBL3322268 0.76 LPL (0.45) MTNR1BCA2PDGFRBKDRCA1
SCHEMBL118986 0.75 CA1 (0.51) MTNR1BCA2PDGFRBKDRCA1
SCHEMBL10174975 0.75 MEN1 (0.47) HIF1APDGFRBKDR
SCHEMBL11925795 0.74 L3MBTL1 (0.39) KDRNR1I2
SCHEMBL441229 0.72 ROCK1 (0.39) HIF1ACA2PDGFRBKDRCA1
SCHEMBL30483059 0.70 SMN1; SMN2 (0.42) MTNR1BNR1I2
SCHEMBL15693723 0.70 L3MBTL1 (0.39) F2PRSS1CA2PDGFRBKDR
SCHEMBL23712499 0.69 CA1 (0.38) CA2AAK1CA1CA9
SCHEMBL30345334 0.69 CA1 (0.38) CA2AAK1CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722687-B2 Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy ASTEX THERAPEUTICS LTD (GB) 2014-05-13 US disclosed
EP-2419428-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY Astex Therapeutics Ltd. (GB) 2012-02-22 EP disclosed
US-20120041000-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY ASTEX THERAPEUTICS LIMITED (GB) 2012-02-16 US disclosed
WO-2010119285-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY ASTEX THERAPEUTICS LIMITED (GB) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041000-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY FGFR1, FGFR3, FGFR2 PIK3CA 39/4885MAPK8 285/4885MAPK9 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.